Jeff Albers

Albers was CEO of Blueprint Medicines until 2022, where he led the company through an initial public offering and evolved it into a precision medicine company. Previously, he was president of Algeta, ahead of its acquisition by Bayer, and held senior commercial and corporate development positions at Genzyme, including vice president of the U.S. hematology and oncology business unit.

  • March 2023

Added to: MOMA Therapeutics - Brighton, MA

MOMA Therapeutics is a biopharmaceutical company.